|
|
楼主 |
发表于 2015-8-13 21:26:48
|
显示全部楼层
3 x/ e% l; p, Z* y, F, q8 KVaccines, 6th Edition
5 V* W2 C% L( P! c) f; T4 Y3 k/ Q
7 @: t6 i. ~: _ QApply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice./ }7 ?4 f1 q; q0 ]
9 X6 N5 K- U' J9 V: J% F5 p" Phttp://yun.baidu.com/share/link? ... 1&uk=3810996606
6 U6 N: h7 O* O1 W4 w' Y- N& X5 g. ]1 l6 m7 f q) p2 V" F
SECTION 1: General aspects of vaccination& |+ d* I: v, e+ \9 I
1 A short history of vaccination 1
1 r3 f( | ?6 A& }# v2 Vaccine immunology 142 K6 _: C" j. |4 K1 Z0 Z& g
3 The vaccine industry 335 A' W" ]3 T+ f( y
4 Vaccine manufacturing 44
; H2 |1 P) p6 A) k4 H" t' \5 Evolution of adjuvants across the centuries 58
1 M+ E1 O( y, k. ]6 Vaccine additives and manufacturing residuals in the United States:, n) z+ g4 B' d+ R, O5 O
licensed vaccines 710 \* d4 q' X* W: k' w5 k
7 Passive immunization 80& J- {0 N1 B; x
8 General immunization practices 88
: N5 r) J$ B, v% V6 h! d% f6 |/ hSECTION 2: Licensed vaccines
# }8 ~/ ?) H. f- T! _& i* a. {9 `3 A9 Adenovirus vaccines 113
: q: w2 m! @5 e h# m10 Anthrax vaccines 127
7 V3 j0 i0 N" S H4 k7 u2 D11 Cholera vaccines 141* W1 D* _' o5 C! V. U' s% q
12 Diphtheria toxoid 153
- a7 t4 [! Z t6 `: w13 Haemophilus influenzae vaccines 167& f: \4 K2 X; P$ \, a* _4 l
14 Hepatitis A vaccines 183
, [4 s( @ f- a: x15 Hepatitis B vaccines 2054 k! X# H1 m) o7 X$ P( M
16 Human papillomavirus vaccines 235# Q, k9 R0 H) n
17 Inactivated influenza vaccines 257& R* O# `+ T8 b% Q; C
18 Influenza vaccine-live 294
5 W3 p. P$ b) z* s19 Japanese encephalitis vaccines 312
! q7 f7 y" ^' M+ c! }; S6 ]" l20 Measles vaccines 352
7 i. H3 w6 F/ E+ y# r0 y21 Meningococcal vaccines 388
% |* B, X; J& s1 l7 z; h7 [( x5 O- A22 Mumps vaccine 419" x, ]+ H! F8 ]+ |0 W* Y: w) Q$ d3 J
23 Pertussis vaccines . 447% I" m' _8 B3 L/ X* v+ f
24 Plague vaccines 4930 I8 l0 ?! P6 F! @) |6 I) j0 H
25 Pneumococcal conjugate vaccine and pneumococcal common protein vaccines 504
/ C1 [$ s& U& V9 X. r26 Pneumococcal polysaccharide vaccines 542
( _) t, ^2 Z3 i% m) J27 Poliovirus vaccine-inactivated . 573) S+ E* @6 g% U# d7 o" N3 D( J0 U
28 Poliovirus vaccine-live 5984 I- L0 n3 V4 N( {2 T
29 Rabies vaccines .646+ y$ L9 z, y- c0 f
30 Rotavirus vaccines . 6698 k' X% t9 i, _' Z
31 Rubella vaccine 688
9 z6 s% I% \6 K* P32 Smallpox and vaccinia 718
: f& M6 a' t- C6 Z5 p33 Tetanus toxoid 746) L$ G3 y$ y5 C8 x7 ^& G3 ]% s
34 Tick-borne encephalitis virus vaccines 7736 q: K% Z- ~% f' i
35 Tuberculosis vaccines 789; Q7 e( ]+ o2 ^0 g/ p$ S
36 Typhoid fever vaccines 8125 @3 _0 J+ d* { W4 }+ g
37 Varicella vaccine 837
& M& y0 |/ ~; Y; _5 \$ v38 Yellow fever vaccine 870" `, u+ J) _( b& b2 O4 @; M/ e
39 Zoster vaccine 969
B, e6 i5 s8 ?; z40 Combination vaccines 981
5 {" k6 C2 V, {# @3 YSECTION 3: Vaccines in development and new vaccine strategies
9 y0 q$ P; e- d. t- F2 A41 Biodefense and special pathogen vaccines 1008# a! K( B' i+ F
42 Therapeutic cancer vaccines 1018
$ P$ z& d+ u/ z# T) x43 Cytomegalovirus vaccines 1032
5 {( T: }; D o1 T44 Dengue vaccines 10421 D* v, a& O+ V! L
45 Diarrhea caused by bacteria 1052
. M* {: q: R' x46 Ebola vaccine 1060
/ h: L+ c. m1 {! c/ @+ B1 y8 f47 Epstein-Barr virus vaccines 1068! @$ C, T R+ G) n3 [
48 Hepatitis C vaccines 10749 a+ W7 N% _% |& _3 n8 x
49 Hepatitis E vaccines 1085/ ~* F0 b0 Q' ~3 S8 r
50 Herpes simplex virus vaccines 10902 W# x% K3 V1 J( e% k* ^# _
51 Human immunodeficiency virus vaccines 1097) W3 O/ ] y: f0 Z$ [/ i# `, r0 p
52 Lyme disease vaccines 11221 r" T5 ~. ?" h' Z6 ]$ x
53 Malaria vaccines 1133
+ \+ w% S& b( [; ~- g- _# h: }54 Noninfectious disease vaccines 1138
% l& E0 ]3 K' E7 B) b2 e* a, e& C+ @55 Respiratory syncytial virus and parainfluenza virus vaccines 1146# ?. E* }' l5 }6 L% r
56 Parasitic disease vaccines 1154 o/ j) v$ M' {3 p, G Y1 R
57 Staphylococcus aureus vaccines 1161
0 z, T8 w1 H* e. d58 Streptococcus group A vaccines 1169
" Z& B. j2 G& z- U+ ], q6 w3 y59 Streptococcus group B vaccines 11765 I/ N3 O# b* }' k" ^
60 Technologies for making new vaccines 1182
" g5 y, [/ H! q# U0 w# I; i) P1 v% W61 Alternative vaccine delivery methods 1200
: U4 A$ [6 i8 B# }/ Q62 The development of gene-based vectors for immunization 12327 X7 v9 n6 I% h0 I
SECTION 4: Vaccination of special groups
6 U8 J) [% T! W0 ~63 Vaccination of immunocompromised hosts 1243
4 r! R( i3 e$ u/ w/ a, }64 Vaccination of human immunodeficiency virus-infected persons 1257
& x9 e7 X7 n* _( `$ C" K65 Vaccines for international travel 1270( I2 a! c7 r/ a/ }
66 Vaccines for health care personnel 12905 I$ t+ E. Q1 S, @- V0 k, ?8 R
SECTION 5: Public health and regulatory issues1 R8 w7 c" d. @! ?7 D& ]: a
67 Immunization in the United States 1310
0 _6 K1 e l$ i- w" O68 Immunization in Europe . 1334
& |1 J. ^% x1 b! }( s69 Immunization in the Asia-Pacific region 1353* P, W7 {8 u) [
70 Immunization in developing countries 1369
+ y L/ l; u: _7 B71 Community immunity 13950 u0 u& r) F$ d0 @
72 Economic analyses of vaccine policies 14130 D8 @0 O+ z# t6 }/ I" M4 F! z
73 Regulation and testing of vaccines 1427' h/ l6 W* @5 i3 S6 `; u
74 Regulation of vaccines in Europe 1447
; |) G! v, v7 @) d# b4 D& G75 Regulation of vaccines in developing countries 1454
+ Y, J: `, S9 Z76 Vaccine safety 1464# u3 w0 b- E* j
77 Legal issues . 1481( x' u9 @* x$ i: T
78 Ethics 1508
% Y# |, n9 R7 F' c" S8 X F$ ]9 N: L7 R$ ~$ H/ S1 \: t3 l
; P3 | z5 n7 b. P6 `( W' R
|
|